title: Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
abstract: BACKGROUND
  There is a close link between hyperlipidemia/dyslipidemia and erectile dysfunction (ED), with endothelial dysfunction as a common mechanism. Both ED and hyperlipidemia/dyslipidemia are rising in prevalence with mounting evidence that these conditions are harbingers of cardiovascular disease.
  
  
  OBJECTIVE
  This review was conducted to provide an update on the epidemiology and oral therapy of both dyslipidemia and ED, the connection between these two conditions, and clinical outcomes relating to the use of statins and phosphodiesterase type-5 (PDE5) inhibitors in men with ED who have associated dyslipidemia.
  
  
  METHODS
  A systematic search was performed of MEDLINE and EMBASE research databases to obtain articles pertaining to the epidemiology, mechanism, and clinical outcomes of statins and PDE5 inhibitors in men with ED and associated dyslipidemia.
  
  
  METHODS
  The clinical and preclinical studies related to ED and dyslipidemia are analyzed and their findings are assessed and summarized. Results. Hyperlipidemia/Dyslipidemia constitute a vascular risk factor having a considerable impact on erectile function. Furthermore, the role of endothelial dysfunction in the pathophysiology of both ED and dyslipidemia is paramount suggesting the importance of comanaging these conditions. Therefore, hyperlipidemia/dyslipidemia when present in patients with ED should prompt management with diet/exercise as well as appropriate pharmacotherapy. With ED being often associated with comorbidities, the use of concomitant pharmacotherapies enhances opportunities for managing the overall global cardiometabolic risk. Newer studies assessing the effect of PDE5 inhibitors in men with dyslipidemia will shed more light on the clinical profile of these agents when used in this patient population.
  
  
  CONCLUSIONS
  While dyslipidemia and ED are important concerns for clinicians, there exists a gap that needs to be closed between the number of individuals who have either or both conditions and those who are receiving appropriate therapy based on evidence and patient-driven goals regarding clinical outcomes.
authors.affiliation: Men's Health Center, The Miriam Hospital, Warren Alpert School of Medicine, Brown University, Swansea, MA, USA;. Electronic address: Martin_Miner@Brown.edu.
authors.forename: Martin
authors.initials: M
authors.lastname: Miner
authors.affiliation: Department of Urology, University of Minnesota School of Medicine, VA Medical Center, Minneapolis, MN, USA.
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Billups
mesh_terms: D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010726:Phosphodiesterase Inhibitors